Molecular Partners Class Action Loss Submission Form

(i) the Company’s product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization (“EUA”); (iii) waning global rates of COVID-19 significantly reduced the Company’s chances of securing EUA for ensovibep; (iv) another of the Company’s product candidates, MP0310, was less attractive to Molecular Partners’ collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company’s initial public offer and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.